The World Market for Prescription Gastrointestinal Drugs

Table of Contents

Chapter One: Executive Summary

• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting the Global Market
• Leading Competitors

Chapter Two: Introduction

• History and Growth of the Industry
• Structure and Organization of the Gastrointestinal Tract
• Gastrointestinal Motility
• Lifetime Gastrointestinal Function

Chapter Three: Antiemetics

• Overview
  • Gastrointestinal Conditions
  • Vomiting
  • Prevalence and Incidence
• Description of Products
  • Receptor Antagonists
  • Phenothiazines
• Metoclopramide and Other Drugs
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
• Competitive Analysis

Chapter Four: Heartburn, GERD, Ulcer Agents

• Overview
• Conditions
• Heartburn
• GERD
• Incidence

• Description of Products
  • Histamine H2-Receptor Antagonists
  • Proton Pump Inhibitors
• Research and Development
• Market Size and Growth
  • World Market
  • U.S. Market
• Competitive Analysis

Chapter Five: Gastrointestinal Cancer Agents

• Overview
  • Gastrointestinal Conditions
  • Colorectal Cancer
  • Esophageal Cancer
  • Stomach Cancer
  • Prevalence and Incidence
• Description of Products
• Research and Development
  • Awaiting Approval and Phase III
  • Other Phase Trials
• Market Size and Growth
• World Market
• U.S. Market
• Competitive Analysis

Chapter Six: Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments

• Overview
  • Conditions
  • Crohn's Disease and Ulcerative Colitis
  • Diverticular Disease
  • Irritable Bowel Syndrome
  • Prevalence and Incidence
• Description of Products
• Research and Development
  • Awaiting Approval and Phase III
  • Other Phase Trials
• Market Size and Growth
  • World Market
  • U.S. Market
  • Competitive Analysis

Chapter Seven: Other Gastrointestinal Drugs

• Overview
  • Conditions
  • Celiac Disease
  • Short Bowel Syndrome
  • Constipation
  • Diarrhea
  • Intestinal Obstruction
  • Digestive Enzyme Disorders
  • Prevalence and Incidence
• Description of Products
• Research and Development
  • Awaiting Approval and Phase III
  • Other Product Development Stages
• Market Size and Growth
  • World Market
  • U.S. Market
• Competitive Analysis

Chapter Eight: Issues and Trends

• Patent Expiration Tactics
• Rx-to-OTC
• PillCam ESO
• Virtual Colonoscopy
• Insurance Coverage Issues
• Smoking and Crohn's Disease
• Smoking and Ulcerative Colitis
• Dark Chocolate and Diarrhea

Chapter Nine: Total Market Size and Forecast

• Overview
• Total Market Size and Forecast
• Markets by Segments
• Competitor Analysis

Chapter Ten: Corporate Profiles

• Introduction
• Altana Pharma AG
• Astellas Pharma Inc.
• AstraZeneca plc
• Axcan Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Centocor, Inc.
• Eisai, Inc.
• Genentech, Inc.
• GlaxoSmithKline plc
• Janssen L.P.
• Merck & Company, Inc.
• Novartis International AG
• Pfizer, Inc.
• Procter and Gamble
• Roche Group
• Salix Pharmaceuticals, Inc.
• Sanofi-Aventis
• Solvay SA
• Takeda Chemical Industries, Ltd.
• TAP Pharmaceutical Products, Inc.
• Wyeth

Appendix: Company Directory

List of Exhibits

Chapter One: Executive Summary

• Figure 1-1: Market Summary: World Market Prescription Gastrointestinal Drugs 2003-2010
• Table 1-1: Leading Suppliers Significant Segments of Participation, 2005

Chapter Three: Antiemetics

• Table 3-1: Estimated U.S. and World Incidence of Nausea and Vomiting by Cause (Chemotherapy and Infectious Disease)
• Table 3-2: Currently Available Prescription Antiemetic Agents (Brand Name, Generic Name, Manufacturer, Class)
• Table 3-3: Antiemetics in Development (Product, Developer, Phase, Indication, Projected Approval Date)
• Table 3-4: World Market for Prescription Antiemetics 2003-2010
• Table 3-5: World Market for Prescription Antiemetics (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
• Table 3-6: Market for Prescription Antiemetics Leading Suppliers' Revenues and Market Share 2005 and Projected 2010

Chapter Four: Heartburn, GERD, Ulcer Agents

• Table 4-1: Estimated World and U.S. Incidence of Heartburn/Indigestion (Daily vs Monthly) and Diagnosed GERD
• Table 4-2: Currently Available Prescription Antacid Agents (Brand Name, Generic Name, Manufacturer, Class)
• Table 4-3: Antacids/Antiulcer Agents in Research and Development (Product, Developer, Development Phase, Indication, Projected Approval Date)
• Table 4-4: World Market for Prescription Antacids/Antiulcer Agents 2003-2010
• Table 4-5: World Market Prescription Antacid/Antiulcer Agents by Product Type (H2-Antagonists, Proton Pump Inhibitors, Others) 2003-2010
• Table 4-6: World Market for Prescription Antacids/Antiulcer Agents (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
• Table 4-7: Market for Prescription Antacids/Antiulcer Agents Leading Suppliers' Revenues and Market Share 2005 and Projected 2010
• Table 4-8: Prescription Antacid/Antiulcer Agents Estimated Revenues and Market Share by Leading Drug 2005

Chapter Five: Gastrointestinal Cancer Agents

• Table 5-1: Estimated U.S. and World Incidence and Mortality of Gastrointestinal Cancers by Type
• Table 5-2: Currently Available Gastrointestinal Cancer Drugs (Brand Name, Generic Name, Manufacturer, Indication)
• Table 5-3: GI Cancer Agents in Research and Development (Product, Developer, Phase, Class, Indication, Projected Approval Date)
• Table 5-4: World Market for Gastrointestinal Cancer Drugs 2003-2010
• Table 5-5: World Market for Gastrointestinal Cancer Drugs by Product Type (Immunotherapy vs Chemotherapy) 2003-2010
• Table 5-6: World Market for Gastrointestinal Cancer Drugs (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
• Table 5-7: Market for Gastrointestinal Cancer Drugs Leading Suppliers' Revenues and Market Share 2005 and Projected 2010
• Table 5-8: Prescription Antacid/Antiulcer Agents Estimated Revenues and Market Share by Leading Drug 2005

Chapter Six: Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments

• Table 6-1: Estimated World and U.S. Prevalence of Crohn's Disease, Irritable Bowel Syndrome, and Related Conditions
• Table 6-2: Currently Available Prescription Drugs for Crohn's, IBS, Ulcerative Colitis, and Related Conditions (Brand Name, Generic Name, Manufacturer, Indication)
• Table 6-3: Antacids/Antiulcer Agents in Research and Development (Product, Developer, Development Phase, Class of Drug, Indication, Projected Approval Date)
• Table 6-4: World Market for Prescription Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments 2003-2010
• Table 6-5: World Market Prescription Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments by Product Type (Anti-inflammatories, Antispasmodics, Others) 2003-2010
• Table 6-6: World Market for Prescription Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
• Table 6-7: Market for Prescription Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments Leading Suppliers' Revenues and Market Share 2005 and Projected 2010
• Table 6-8: Prescription Crohn's Disease, Irritable Bowel Syndrome, and Ulcerative Colitis Treatments: Estimated Revenues and Market Share by Leading Drug 2005

Chapter Seven: Other Gastrointestinal Drugs

• Table 7-1: Estimated World and U.S. Incidence of Other GI Conditions (Diarrhia, Giardiasis, Opioid-Induced Constipation, Digestive Enzyme Disortders)
• Table 7-2: Currently Available Prescription Products to Treat Other GI C onditions (Brand Name, Generic Name, Manufacturer, Indication)
• Table 7-3: Other GI Agents in Research and Development (Product, Developer, Development Phase, Drug Class, Indication, Projected Approval Date)
• Table 7-4: World Market for Other Prescription GI Drugs 2003-2010
• Table 7-5: World Market for Other Prescription GI Drugs by Product Type (Anti-Infectives, Enzymes, Others) 2003-2010
• Table 7-6: World Market for Other Prescription GI Drugs (U.S. Revenues vs Non-U.S. Revenues) 2003-2010
• Table 7-7: Market for Prescription Antacids/Antiulcer Agents Leading S uppliers' Revenues and Market Share 2005 and Projected 2010

Chapter Eight: Issues and Trends

• Table 8-1: Prominent Gastrointestinal Drug Patent Expirations through 2010

Chapter Nine: Total Market Size and Forecast

• Table 9-1: World Market for Prescription Gastronintestinal Drugs 2003-2010
• Table 9-2: World Market Prescription Gastrointestinal Drugs by Product Type, 2003-2010
• Figure 9-1: Trending in the World Market for Prescription Gastrointestinal Drugs by Product Type 2003-2010
• Figure 9-2: World Market Prescription Gastrointestinal Drugs by Percent and Product Type, 2005 Table 9-3: Prescription Gastrointestinal Drugs: Leading Suppliers' Significant Segments of Participation, 2005